CroíValve expand patent portfolio

“CroíValve, a Dublin based medical device company developing a novel treatment for tricuspid regurgitation, are pleased to announce that they have expanded their existing patent portfolio with the addition of two newly granted US Patents.

This adds to the existing patent portfolio which protects the Company’s intellectual property surrounding a novel method to treat Tricuspid Regurgitation. In addition to these new patents, CroíValve are pursing global patent protection across multiple jurisdictions. CroíValve also has a number of new filings with the US Patent and Trademark Office (USPTO) to expand their IP protection as they continue to innovate their novel technology.

Reacting to this news, CroíValve CEO Lucy O’Keeffe said “CroíValve is committed to developing a novel solution for Tricuspid Regurgitation to meet the large unmet need in patients today. This expansion of our IP portfolio further protects our highly novel technology”.

About Tricuspid Regurgitation

Tricuspid regurgitation (TR) is a severe heart condition that occurs when the tricuspid valve fails to close properly. This results in blood being pumped backwards into the right atrium and venous system causing debilitating symptoms.”